[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_94":95},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","knmt7iphqlm3fsxpt09l2nj08","revision",2,"title","Lakefront Biotherapeutics 6-K 文件发布","originalTitle","6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)","summary","Lakefront Biotherapeutics 发布 6-K 文件，包含 2026 年 10 月财务信息。文件引用了 10 月 6 日发布的新闻稿，附有 Exhibit 99.1。该文件已纳入公司多个 S-8 注册声明中。","reason","source",{"_11":84,"_85":86,"_87":88,"_89":57,"_90":91,"_92":93},"links",{"_81":82,"_63":83},"publishedAt","2026-10-06T20:55:50.000Z","discoveredAt","2026-10-06T22:04:16.381Z","timelineAt","category","tip","tags",[79,80],"stockSymbols",[],"score",20,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fB42XVa_7Lmo",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","3931bf70-2b9c-41ad-91d6-015fa625d615",{"_72":73,"_15":16},"zh","

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On October 6, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated October 6, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Lakefront Biotherapeutics
		(Registrant)


Date: October 6, 2026		/s/ Ying Deng
		Ying Deng
		Authorized Officer

","zhKind","complete","政策与监管","退市","aihot","/items/knmt7iphqlm3fsxpt09l2nj08","https://www.sec.gov/Archives/edgar/data/1421876/000117184326006469/0001171843-26-006469-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791504000&sig=503fb7d170765eee","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791504000&sig=bd7a734cec863d9b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791504000&sig=e5a5cfd96e0c1fd2 96w","changelogVersion","2026-10-01T08:00"]